Prothena Co. PLC (NASDAQ:PRTA) has received an average recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $44.44.
A number of research firms have recently weighed in on PRTA. Zacks Investment Research lowered Prothena from a “buy” rating to a “hold” rating in a research note on Thursday, April 26th. Oppenheimer reissued a “hold” rating on shares of Prothena in a research note on Wednesday, May 9th. Nomura dropped their price objective on Prothena from $87.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, April 24th. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 price objective (up previously from $14.00) on shares of Prothena in a research note on Friday, June 15th. Finally, Barclays lowered Prothena from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 23
NASDAQ PRTA traded up $0.04 on Friday, reaching $14.94. 342,156 shares of the company’s stock traded hands, compared to its average volume of 731,713. The stock has a market capitalization of $594.94 million, a P/E ratio of -3.67 and a beta of 2.92. Prothena has a 12 month low of $10.43 and a 12 month high of $70.00.
Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.03). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $31.45 million. Prothena had a negative net margin of 606.09% and a negative return on equity of 38.08%. sell-side analysts forecast that Prothena will post -3.68 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Woodford Investment Management Ltd lifted its stake in Prothena by 0.3% in the first quarter. Woodford Investment Management Ltd now owns 11,557,614 shares of the biotechnology company’s stock worth $424,280,000 after acquiring an additional 29,000 shares during the period. Palo Alto Investors LP lifted its stake in Prothena by 0.5% in the first quarter. Palo Alto Investors LP now owns 1,101,338 shares of the biotechnology company’s stock worth $40,430,000 after acquiring an additional 5,683 shares during the period. BB Biotech AG lifted its stake in Prothena by 14.3% in the first quarter. BB Biotech AG now owns 400,000 shares of the biotechnology company’s stock worth $14,684,000 after acquiring an additional 50,000 shares during the period. Deutsche Bank AG lifted its stake in Prothena by 37.8% in the fourth quarter. Deutsche Bank AG now owns 231,468 shares of the biotechnology company’s stock worth $8,674,000 after acquiring an additional 63,537 shares during the period. Finally, Employees Retirement System of Texas lifted its stake in Prothena by 24.2% in the first quarter. Employees Retirement System of Texas now owns 113,000 shares of the biotechnology company’s stock worth $4,148,000 after acquiring an additional 22,000 shares during the period.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.